1. Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy.

    Neurobiology of Aging 44:108 (2016) PMID 27318138 PMCID PMC4926954

    Age at onset (AAO) has been shown to influence the phenotype of Alzheimer's disease (AD), but how it affects atypical presentations of AD remains unknown. Posterior cortical atrophy (PCA) is the most common form of atypical AD. In this study, we aimed to investigate the effect of AAO on cortical...
  2. Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease.

    Alzheimer's & Dementia 12(8):862 (2016) PMID 26993346

    The genetics underlying posterior cortical atrophy (PCA), typically a rare variant of Alzheimer's disease (AD), remain uncertain. We genotyped 302 PCA patients from 11 centers, calculated risk at 24 loci for AD/DLB and performed an exploratory genome-wide association study. We confirm that varia...
  3. Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.

    Canadian Journal of Neurological Sciences 43(4):503 (2016) PMID 26916179

    Positron emission tomography (PET) imaging of brain amyloid beta is now clinically available in several countries including the United States and the United Kingdom, but not Canada. It has become an established technique in the field of neuroimaging of aging and dementia, with data incorporated ...
  4. Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.

    JAMA Neurology 73(6):691 (2016) PMID 27088644 PMCID PMC4905783

    Late-onset Alzheimer disease (AD), the most common form of dementia, places a large burden on families and society. Although epidemiological and clinical evidence suggests a relationship between inflammation and AD, their relationship is not well understood and could have implications for treatm...
  5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

    Brain 139(Pt 5):1551 (2016) PMID 26962052

    SEE SARAZIN ET AL DOI101093/BRAIN/AWW041 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The advent of the positron emission tomography tracer (18)F-AV1451 provides the unique opportunity to visualize the regional distribution of tau pathology in the living human brain. In this study, we tested the...
  6. Amyloid biomarkers: pushing the limits of early detection.

    Brain 139(Pt 4):1008 (2016) PMID 27012491

  7. Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.

    Alzheimer's & Dementia 12(4):510 (2016) PMID 27103054

    Alzheimer's disease research has often focused on the molecular brain changes that promote memory loss and other dementia-related cognitive impairments. Many studies, for example, have used positron emission tomography (PET) imaging to measure brain levels of the beta-amyloid protein, a key mole...
  8. PET Imaging of Tau Deposition in the Aging Human Brain.

    Neuron 89(5):971 (2016) PMID 26938442 PMCID PMC4779187

    Tau pathology is a hallmark of Alzheimer's disease (AD) but also occurs in normal cognitive aging. Using the tau PET agent (18)F-AV-1451, we examined retention patterns in cognitively normal older people in relation to young controls and AD patients. Age and β-amyloid (measured using PiB PET) we...
  9. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

    Alzheimer's & Dementia 12(3):292 (2016) PMID 27012484

    During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence o...
  10. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage.

    Neurology 86(7):600 (2016) PMID 26802093 PMCID PMC4762418

    To characterize the cognitive and neuropsychiatric symptoms of patients with behavioral variant frontotemporal dementia (bvFTD) over the natural course of the disease. We examined the initial and subsequent neuropsychological test performance and neuropsychiatric symptoms in a large cohort of pa...
  11. Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?

    Neurocase 22(2):161 (2016) PMID 26304661 PMCID PMC4733403

    We report a diagnostically challenging case of a 64-year-old man with a history of remote head trauma who developed mild behavioral changes and dyscalculia. He was diagnosed with clinical Alzheimer's disease (AD), with additional features consistent with behavioral variant frontotemporal dementi...
  12. Amyloid in dementia associated with familial FTLD: not an innocent bystander.

    Neurocase 22(1):76 (2016) PMID 26040468 PMCID PMC4662906

    Patients with frontotemporal lobar degeneration (FTLD) can show superimposed amyloid pathology, though the impact of amyloid on the clinical presentation of FTLD is not well characterized. This cross-sectional case-control study compared clinical features, fluorodeoxyglucose-positron emission to...
  13. MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes.

    Alzheimer's & dementia : diagnosis, assessment ... 3:91 (2016) PMID 27453930 PMCID PMC4941041

    MCP-1 and eotaxin-1 are encoded on chromosome 17 and have been shown to reduce hippocampal neurogenesis in mice. We investigated whether these chemokines selectively associate with memory in individuals with mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia. MCP-1 and eotaxin...
  14. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.

    Journal of Alzheimer's Disease 51(2):339 (2016) PMID 26836192

    It is unclear whether the distribution of tau pathology differs between cases with early-onset familial Alzheimer's disease (AD) and sporadic AD. We present positron emission tomography (PET) data from a young patient with a presenilin-1 mutation (Thr116Asn). 18F-flutemetamol PET showed a distri...
  15. Cavum Septum Pellucidum in Retired American Pro-Football Players.

    Journal of Neurotrauma 33(1):157 (2016) PMID 25970145 PMCID PMC4696427

    Previous studies report that cavum septum pellucidum (CSP) is frequent among athletes with a history of repeated traumatic brain injury (TBI), such as boxers. Few studies of CSP in athletes, however, have assessed detailed features of the septum pellucidum in a case-control fashion. This is impo...
  16. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease.

    Human Brain Mapping 36(11):4421 (2015) PMID 26260856 PMCID PMC4692964

    Alzheimer's disease (AD) can present with distinct clinical variants. Identifying the earliest neurodegenerative changes associated with each variant has implications for early diagnosis, and for understanding the mechanisms that underlie regional vulnerability and disease progression in AD. We ...
  17. Loss of functional connectivity is greater outside the default mode network in nonfamilial early-onset Alzheimer's disease variants.

    Neurobiology of Aging 36(10):2678 (2015) PMID 26242705 PMCID PMC4698410

    The common and specific involvement of brain networks in clinical variants of Alzheimer's disease (AD) is not well understood. We performed task-free ("resting-state") functional imaging in 60 nonfamilial AD patients, including 20 early-onset AD (age at onset <65 years, amnestic/dysexecutive def...
  18. Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.

    Alzheimer's & dementia : diagnosis, assessment ... 1(3):358 (2015) PMID 27239516 PMCID PMC4878065

    Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detected...
  19. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.

    Brain 138(Pt 9):2732 (2015) PMID 26141491 PMCID PMC4623840

    A 'frontal variant of Alzheimer's disease' has been described in patients with predominant behavioural or dysexecutive deficits caused by Alzheimer's disease pathology. The description of this rare Alzheimer's disease phenotype has been limited to case reports and small series, and many clinical...
  20. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

    Neurobiology of Aging 36(8):2340 (2015) PMID 25990306 PMCID PMC4465267

    Different clinical variants of probable Alzheimer's disease (AD) share underlying plaques and tangles but show distinct atrophy patterns. We included 52 posterior cortical atrophy, 29 logopenic variant primary progressive aphasia, 53 early-onset and 42 late-onset AD patients, selected for abnorm...